1369509-72-7 Usage
General Description
5-Bromo-3-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazolo[3,4-c]pyridine, also known as BIPPP, is a synthetic chemical compound with a complex molecular structure. It belongs to the pyrazolo[3,4-c]pyridine class of compounds, which have potential pharmaceutical applications. BIPPP is often used as a building block or precursor in the synthesis of various biologically active molecules, such as potential drugs or pharmaceutical intermediates. The presence of bromine and iodine atoms in its structure makes BIPPP a valuable tool for chemical synthesis and medicinal chemistry research. Its unique molecular framework and properties make it a subject of interest for drug discovery and development efforts.
Check Digit Verification of cas no
The CAS Registry Mumber 1369509-72-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,6,9,5,0 and 9 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1369509-72:
(9*1)+(8*3)+(7*6)+(6*9)+(5*5)+(4*0)+(3*9)+(2*7)+(1*2)=197
197 % 10 = 7
So 1369509-72-7 is a valid CAS Registry Number.
1369509-72-7Relevant articles and documents
Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors
Hu, Huiyong,Wang, Xiaojing,Chan, Grace Ka Yan,Chang, Jae H.,Do, Steven,Drummond, Jake,Ebens, Allen,Lee, Wendy,Ly, Justin,Lyssikatos, Joseph P.,Murray, Jeremy,Moffat, John G.,Chao, Qi,Tsui, Vickie,Wallweber, Heidi,Kolesnikov, Aleksandr
, p. 5258 - 5264 (2015/11/09)
Pim kinase inhibitors are promising cancer therapeutics. Pim-2, among the three Pim isoforms, plays a critical role in multiple myeloma yet inhibition of Pim-2 is challenging due to its high affinity for ATP. A co-crystal structure of a screening hit 1 bound to Pim-1 kinase revealed the key binding interactions of its indazole core within the ATP binding site. Screening of analogous core fragments afforded 1H-pyrazolo[3,4-c]pyridine (6-azaindazole) as a core for the development of pan-Pim inhibitors. Fragment and structure based drug design led to identification of the series with picomolar biochemical potency against all three Pim isoforms. Desirable cellular potency was also achieved.
